# An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency

> **NCT02376751** · — · NO_LONGER_AVAILABLE · sponsor: **Alexion Pharmaceuticals, Inc.**

## Conditions studied

- Lysosomal Acid Lipase Deficiency

## Interventions

- **DRUG:** sebelipase alfa

## Key facts

- **NCT ID:** NCT02376751
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2016-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02376751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02376751, "An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02376751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*